HanchorBio Inc (TPEx:7827), a clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, announced on Monday that it has entered into a strategic collaboration agreement with WuXi Biologics (HK:2269), a Contract Research, Development, and Manufacturing Organisation (CRDMO).

This collaboration is intended to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programmes from HanchorBio's pipeline.

WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The companies say that the collaboration is designed to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB) platform.